Author/Authors :
Rahab, Mehdi Hazrat-E-Rasoul Akram Hospital - Iran University of Medical Science , Heydarpour, Evaz Rajaie Cardiovascular - Medical and Research Center, Tehran , Totonchi, Ziae Rajaie Cardiovascular - Medical and Research Center, Tehran , Kachoueian, Naser Department of Cardiovascular Surgery - School of Medicine - Shahid Beheshti University of Medical Sciences , Zeraatiannejad Davani, Sam Department of General Surgery - School of Medicine - Hazrat-e Rasool General Hospital - Iran University of Medical Sciences , Mesbah Kiaei, Mehrdad Department of Anesthesiology - School of Medicine - Hasheminejad Kidney Center - Iran University of Medical Sciences , Mehrabanian, Mohammad Javad Department of Anesthesiology - School of Medicine - Tehran Heart Center - Tehran University of Medical Sciences , Panahi, Masoumeh Rajaie Cardiovascular - Medical and Research Center - Iran University of Medical Sciences , Ahmadvand, Parnian Hazrat-E-Rasoul Akram Hospital - Iran University of Medical Science , Kharazani, Samaneh Rajaie Cardiovascular - Medical and Research Center - Iran University of Medical Sciences , Mortazian, Meysam AJA University of Medical Sciences
Abstract :
Background: This study was carried out to determine the effects of dexmedetomidine on clinical outcomes and renal function after coronary artery bypass grafting (CABG) to address the increased rate of CABG? and the importance of modification in stress responses and control of adverse effects on renal function and with the aim of cost reduction.
Materials and Methods: This double-blind randomized clinical trial was carried out with the participation of 129 subjects under elective CABG in Rajaei Heart Center, Tehran, Iran in 2017. Patients were randomly assigned to four groups with simple randomization including one placebo (normal saline infusion) group and three dexmedetomidine groups; 0.5 µg/kg/h on CPB, 0.5 µg/kg/h in 24 hours, and 0.75 µg/kg/h in 24 hours. The blood pressure, blood urea nitrogen (BUN), serum creatinine, transfused blood volume, urine volume, and hemofiltration on pump and lactate were assessed at different time intervals. Results: Results showed more stability especially in central venous pressure (CVP) (p=0.001) and systolic blood pressure (p=0.006) in the groups receiving dexmedetomidine 0.75 µg/kg/h per 24 hours. But diastolic blood pressure and heart rate were the same across the groups (p>0.05). All other variables including hepatic and renal function tests were the same across the groups (P>0.05).
Conclusion: Overall, according to the obtained results in the current study, it may be concluded that dexmedetomidine would have some promising effects on hemodynamic stability but there are no obvious renoprotective effects for this medication.
